Pharmacologic Management of Bipolar‑Spectrum Mood Swings in Adolescents

First‑Line Medication Options

Lithium is the only FDA‑approved mood stabilizer for adolescents ≥ 12 years with bipolar disorder, showing acute mania response rates of 38–62 % and superior long‑term maintenance efficacy; it also reduces suicide attempts by ~8.6‑fold and completed suicides by ~9‑fold. (Strength of evidence: high) 1
Valproate yields higher acute response (≈ 53 %) than lithium (≈ 38 %) in youth with mania or mixed episodes and is especially effective for irritability, agitation, and aggression, but carries risks of polycystic ovary syndrome in females and requires hepatic monitoring. (Strength of evidence: moderate) 1
Atypical antipsychotics (aripiprazole, risperidone, quetiapine, olanzapine) are endorsed as first‑line alternatives; aripiprazole 10 mg/day and risperidone 0.5–2.5 mg/day have demonstrated efficacy in pediatric trials, with no added benefit at higher doses. (Strength of evidence: moderate) 1

Start lithium when the adolescent can adhere to regular serum‑level, renal, and thyroid monitoring, when suicide risk is present, when long‑term relapse prevention is a priority, or when minimal sedation is desired. 1
Choose valproate when prominent irritability, agitation, or aggression dominate, when mixed or rapid‑cycling episodes are evident, or when lithium’s renal/thyroid side‑effects are contraindicating. 1
Select an atypical antipsychotic when rapid symptom control is needed, when psychotic features accompany mood symptoms, or after inadequate response to adequate trials of lithium or valproate. 1

Lithium: CBC, thyroid panel (TSH, free T4), urinalysis, BUN, creatinine, serum calcium, and pregnancy test for females.
Valproate: Liver function tests, CBC with platelets, and pregnancy test for females.
Atypical antipsychotics: BMI, waist circumference, blood pressure, fasting glucose, and fasting lipid panel.

Lithium: Begin 300 mg three times daily for patients ≥ 30 kg (900 mg/day) or 300 mg twice daily for < 30 kg (600 mg/day); increase by 300 mg weekly until serum level 0.8–1.2 mEq/L is reached; check level after 5 days at steady state.
Valproate: Start 125 mg twice daily; titrate to achieve therapeutic serum concentration of 50–100 μg/mL; maintain at adequate dose for a 6–8‑week trial before deeming ineffective.
Aripiprazole: Initiate 2 mg/day, titrate to target 10 mg/day over 5 days (10 mg dose as effective as 30 mg).
Risperidone: Begin 0.5 mg/day, titrate to 1–3 mg/day over 7 days (comparable efficacy to 4–6 mg/day with better tolerability).

Combine a mood stabilizer (lithium or valproate) with an atypical antipsychotic for severe or treatment‑resistant presentations. Quetiapine + valproate is more effective than valproate alone for adolescent mania; risperidone combined with lithium or valproate shows efficacy in open‑label studies.
Reserve combination therapy for: inadequate response after 6–8 weeks of monotherapy at therapeutic doses; severe mania with psychotic features; rapid‑cycling or mixed episodes; or documented treatment resistance. 1

Lithium: Serum lithium, renal function, thyroid function, and urinalysis every 3–6 months; during acute treatment, check levels twice weekly until stable.
Valproate: Serum drug level, hepatic function, and hematologic indices every 3–6 months.
Atypical antipsychotics: BMI monthly for the first 3 months then quarterly; blood pressure, fasting glucose, and lipids at 3 months and annually thereafter. 1

Maintain treatment for at least 12–24 months after mood stabilization; many adolescents require lifelong therapy. Discontinuation of lithium leads to relapse in > 90 % of non‑compliant youths versus 37.5 % of compliant patients. (Strength of evidence: high) 1

Lithium: Educate patients and families on early toxicity signs (fine tremor, nausea, diarrhea) and urgent signs (coarse tremor, confusion, ataxia); secure medication to prevent accidental overdose.
Valproate: Perform baseline and periodic liver monitoring; counsel females about the risk of polycystic ovary syndrome.
Atypical antipsychotics: Provide proactive weight‑management counseling due to metabolic side‑effects, especially with olanzapine and quetiapine. 1

Integrate psychoeducation on illness course, treatment options, and adherence with pharmacotherapy. Adding cognitive‑behavioral therapy or family‑focused therapy improves outcomes. Family involvement aids medication supervision, early‑warning sign detection, and restriction of lethal means in suicidal adolescents. 1

ECT may be considered for severely impaired adolescents with manic or depressive episodes when at least two adequate pharmacologic trials have failed or are intolerable; it is reserved for life‑threatening presentations such as refusal to eat/drink, severe suicidality, or uncontrollable mania. (Strength of evidence: moderate) 3